ClinicalTrials.gg
RecruitingNCT06122584Updated Nov 4, 2026

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

A Phase 3 interventional study of [18F]PSMA-1007 in Prostate Cancer, sponsored by ABX advanced biochemical compounds GmbH. Recruiting at 19 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by ABX advanced biochemical compounds GmbH · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 4, 2026Site recruiting status changedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
434
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Prostatic Neoplasms with a site in Germany — 70 open to participants now, 116 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.

Planned enrollment
106th of 269
434 · median 278
Started
2024
with 23 others
Phase 3
109 of 333
13 open now
Primary completion
2027-03
later than 54 of 115 live
Registered
264th of 333
by date

Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 106th largest by planned enrollment of the 269 interventional ones that give a count, is one of 24 that started in 2024, is one of 109 in phase 3, reaches primary completion later than 54 of the 115 other live ones, and was the 264th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Prostatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient (male) is aged 18 years or above.
  2. The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written to participate.
  3. The patient has newly diagnosed, -proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
  4. The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:

    • Overall ISUP grade group 4 or 5,
    • Clinical category T3a or greater,
    • Serum PSA level greater than 20 ng/ml.
  5. The patient has undergone conventional imaging (CT or MRI, and bone scan if clinically indicated) to detect the presence of pelvic nodal involvement and bone or visceral within 60 days of the planned PET-CT procedure.

Exclusion criteria

Exclusion Criteria:

  1. Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.
  2. The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
  3. The patient has any (s) for and/or known to any constituent(s) of [18F]PSMA-1007.
  4. The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).
  5. The patient is closely affiliated to the investigation site; e.g. is a first-degree relative of the investigator.
  6. At the time of screening, the patient is receiving any other agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit.
  7. The patient has previously been enrolled in this trial.
  8. The patient has previously undergone PET imaging with any PSMA-avid product.
  9. The patient has histological evidence of small-cell carcinoma of the prostate.
  10. The patient is clinically unstable or requires emergency treatment.
  11. The patient has any mental condition rendering him incapable of understanding the nature, scope, and consequences of the trial as set out in the information given to the patient.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
434 participants (estimated)

Study arms

  • Experimental
    [18F]PSMA-1007

    Single intravenous administration of \[18F\]PSMA-1007 for Positron Emission Tomography (PET) scan

    Drug: [18F]PSMA-1007

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference

    Time frame: 6 to 8 weeks post-surgery

07

Study locations

14 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 33 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Jun 13, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 4 sites changed recruiting status (3 now completed, 1 now active, not recruiting)
Show 4 sites
  • CHRU de Nancy · Nancy, FranceRecruiting→Completed
  • Klinikum rechts der Isar, TUM · München, GermanyActive, not recruiting→Completed
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" · Meldola, ItalyRecruiting→Completed
  • Hospital Vall d'Hebron · Barcelona, SpainRecruiting→Active, not recruiting
Show site
  • Jikei University Hospital · Tokyo, Japan
Nov 4, 2026
Enrollment
380→434
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added. 4 sites changed recruiting status (3 now completed, 1 now active, not recruiting)
    Show 4 sites
    • CHRU de Nancy · Nancy, FranceRecruiting→Completed
    • Klinikum rechts der Isar, TUM · München, GermanyActive, not recruiting→Completed
    • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" · Meldola, ItalyRecruiting→Completed
    • Hospital Vall d'Hebron · Barcelona, SpainRecruiting→Active, not recruiting
    Show site
    • Jikei University Hospital · Tokyo, Japan
    Enrollment 380→434
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06122584
Lead sponsor
ABX advanced biochemical compounds GmbH
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Jun 13, 2024
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Alexander Hoepping, Dr.
Contact
cd@abx.de
+49 3528 4041 60

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PSMA-1007

Start the discussion